updat proof slurri
tuesday report result review recent progress manag
reiter plan present top-line result on-going phase trial
mid-year could establish poc patient
hyperammonemia phenylketonuria pku respect trial util
formul transit may requir clinic bridg studi view
new formul essenti commerci viabil demonstr
meaning impact serum ammonia next step could includ trial urea cycl
disord ucd indic establish biomarker-bas registr
endpoint cash believ adequ resourc sustain
oper reiter outperform pt
test two clinical-stag product reduc toxic metabolit build-up
symptomat patient data patient clinic trial could
announc manag believ reduct serum
ammonia could repres clinic meaning signal potenti translat
reduc hospit improv cognit function
trial includ sever safeguard minim variabl
cirrhot patient must test posit elev ammonia
five day run-in standard diet addit tight standard
implement sampl collect handl analysi expect result
deliv press releas inform next develop step
top-line data pku patient also expect
expect updat includ result least patient enrol single-
dose multiple-dos cohort small trial size may
insuffici show statist signific phenylalanin reduct manag
indic panel biomark could provid clearer pictur clinic activ
present administ slurri dose
indic pill-bas formul would use futur trial believ
pill-bas formul essenti commerci viabil product
separ ind file intratumor oncolog product
track
report net loss per share lower estim
includ recent mileston payment estim
suffici cash sustain oper revis
forward opex estim reflect addit expenditur
pipelin advanc potenti enter clinic
year price histori
metabol
analyst certif import disclosur see disclosur
success clinic develop
commerci launch treatment
commerci launch treatment
due liver cirrhosi
commerci launch treatment
non-risk-adjust sale
non-risk-adjust sale
believ synthet biotic platform potenti
address wide rang indic includ inborn error
metabol immune-medi disord cancer
valuat current center potenti lead asset
orphan indic ucd
pku well toxic ammonia build-up result liver
potenti initi phase trial ucd
potenti report interim clinic data phase
studi
potenti present data sad/mad phase studi
pku patient
potenti present interim data phase trial
ucd patient
higher project peak sale model indic
earlier anticip regulatori approv commerci
launch and/or
larg non-dilut mileston payment futur
failur and/or gain approv
us eu regulatori author
delay clinic develop commerci timelin
lower anticip commerci uptak and/
price target base risk-adjust sum-of-th part npv contribut ucd
pku includ project cash per share arriv price target round
risk includ price clinic regulatori financ market competit
ucd
potenti initi phase trial ucd patient
potenti present interim data phase trial ucd patient
potenti report interim clinic data phase studi cirrhot
pku
potenti present data sad/mad phase studi pku patient
potenti ind file solid tumor
compani present oppenheim co estim
sec file oppenheim co research
figur thousand except per share expens good sold research develop gener administr oper loss incom expens loss incom incom incom loss unreal loss market incom per share share outstand co mark breidenbach outperform
sec file oppenheim co research
figur thousand except per share asset cash account prepaid expens current current properti equip restrict liabil account accru expens defer defer capit leas current capit leas oblig net current defer rent net current defer revenu net current contingenciespref stockstockhold equitycommon addit paid-in accumul comprehens accumul stockhold liabil stockhold synlog inc
stock price compani mention report
